|Why is my doctor recommending Kaletra and Combivir to start?
Aug 31, 2007
hi there. I tested positive 3 weeks ago and just got my intitial blood work results back. My CD4 is 284 and my viral load is 98,000. The doctor thinks i might have been infected for 3-5 years and has asked me to come back in 4 weeks to repeat the tests before starting treatment. He is suggesting Kaletra (2 tabs twice daily) and Combivir (1 tab twice daily). I have 2 questions - is this a good combination regimen ? and why so many tablets per day ? I hear of 1 tablet per day regiments . I am not co infected with anything else, but i do have slightly high cholesterol. Is he suggesting a large dose to try and rapidly increase my CD4 and decrease my V/L ?
Thanks very much
| Response from Dr. Pierone
Hello, and thanks for posting.
Kaletra is a protease inhibitor combination of ritonavir and lopinavir and is dosed twice daily. It has a long track record, but has more side effects than the combination of ritonavir (Norvir) and atazanavir (Reyataz) and most experienced HIV doctors would use this instead.
In general, NNRTI-based regimens are more effective than protease inhibitor-based treatment. So Atripla (Viread, Emtriva, and Sustiva in combination) one tablet nightly is hard to beat. I would discuss this option with your doctor and see if he still wants to stick to this outmoded cocktail. If so, let us know why.
Get Email Notifications When This Forum Updates or Subscribe With RSS
This forum is designed for educational purposes only, and experts are not rendering medical, mental health, legal or other professional advice or services. If you have or suspect you may have a medical, mental health, legal or other problem that requires advice, consult your own caregiver, attorney or other qualified professional.
Experts appearing on this page are independent and are solely responsible for editing and fact-checking their material. Neither TheBody.com nor any advertiser is the publisher or speaker of posted visitors' questions or the experts' material.